Would you consider neoadjuvant endocrine therapy instead of chemotherapy for a pre-menopausal patient with a node-positive, ER+PR+, lobular breast cancer?
Initial pathology additionally yields low Ki-67 and is HER2 negative.
Answer from: Medical Oncologist at Academic Institution
You can consider neoadjuvant endocrine therapy (NET) for classical strongly ER/PR expressing lobular cancers in certain cases where there is a desire to delay surgery or the patient is not a candidate for chemotherapy. Usually the duration of therapy is for around 6 months as long as the patient is ...